INTERVIEWS

Dr. Arlene Siefker-Radtke, Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center in Houston, TX discusses her presentation at ESMO 2023, abstracts #2362MO and #2359O on Erdafitinib (erda) from the Phase 3 THOR study. For more information visit: https://www.annalsofoncology.org/article/S0923-7534(23)04015-2/fulltext and https://www.nejm.org/doi/full/10.1056/NEJMoa2308849

Dr. Nicolas Girard, Professor of Respiratory Medicine at Versailles Saint Quentin University and head of the Curie-Montsouris Thorax Institute discusses his presentation at ESMO 2023 – Presidential Symposium / Abstract #LBA5 – Amivantamab plus carboplatin/pemetrexed vs carboplatin/pemetrexed as first line treatment in EGFR exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): primary results from PAPILLON, a randomized phase 3 global study.

Dr. Kim Chi, Senior Research Scientist, Vancouver Prostate Centre discusses his presentation at ESMO 2023, abstract #LBA85 – Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE.

Wensheng Fan, CEO and co-founder of Spectral AI, a company that is using artificial intelligence to revolutionize diagnostics and wound care, discusses the recently awarded Biomedical Advanced Research and Development Authority (BARDA) Project BioShield Contract. This contract is for the advanced development of the DeepView � System, the Company’s AI-driven burn wound imaging technology, to be used at emergency departments, trauma centers and burn centers, for both routine burn care and as a medical countermeasure for use in burn mass casualty incidents (BMCI). DeepView ® records imaging data of the wound and uses an AI algorithm to predict wound healing patterns based on a large proprietary clinical database.

Voyce is a technology-driven company dedicated to breaking down language barriers in healthcare. CEO of Voyce, Andrew Royce, discusses how the company delivers simple, seamless, and secure on-demand medical interpretation in more than 240 languages and dialects, 24/7. The app is designed to work with smartphones, tablets, laptops, desktops, iOS, Android, Telephonic and APIs. It is easily integrated into virtual care platforms and EMRs, such as EPIC, Teladoc, and Zoom.

Trial investigator Brian Slomovitz, MD, Director of Gynecologic Oncology and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center, discusses results from the global, randomized, open-label Phase 3 innovaTV 301 trial, which showed treatment with tisotumab vedotin demonstrated statistically significant and clinically meaningful overall survival, progression-free survival, and objective response in recurrent or metastatic cervical cancer patients with disease progression on or after first-line therapy, compared with chemotherapy.

Jeff Hackman, CEO of Comera Life Sciences, discusses how the company uses its proprietary SQore™ viscosity reduction platform to transform intravenous (IV) biologics into subcutaneous (SQ) versions that patients can self-administer in a single dose. High viscosity is a significant hurdle to formulating subcutaneous biologics and Comera’s addition of excipients, such as caffeine, interrupts intermolecular interactions to reduce viscosity of high concentration monoclonal antibody formulations. These self-administered SQ biologics have significant potential benefits over IV infusion for patients and payers. Comera is leveraging its SQore platform in multiple ongoing collaborations with biopharma companies to enhance both commercial biologics and those in early development stages. For more information on Comera Life Sciences, visit https://comeralifesciences.com.

Dr. ​Jeffrey Popma​, MD, Vice President and Chief Medical Officer for Coronary, Renal Denervation, and Structural Heart at Medtronic discusses Medtronic’s recent CE Mark approval for the Evolut™ FX TAVI System and the increased need for solutions for patients with symptomatic severe aortic stenosis.

Dr. Joe Kimura, Chief Medical Officer, discusses how Somatus deployed a robust transitions-of-care (TOC) service to help their patients safely transition from acute inpatient care to home. Somatus provides TOC services to CKD3/4/5 and ESKD patients and has found patients in the program are 49% less likely to be re-admitted to the hospital compared to usual care.   

Dr. Thomas Carroll, Director at Brigham and Women’s Voice Program and the Medical Director of Otolaryngology Clinics at Brigham and Women’s Hospital discusses his presentations from the 2023 American Academy of Head and Neck Surgery conference, hot topics, and current challenges in the field of ENT.